An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
|Videos|September 10, 2018
Will Specialty Pharmacies Become the New Norm in the Future?
Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses the potential for specialty pharmacies to become the norm.
Advertisement
Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses the potential for specialty pharmacies to become the norm.
Transcript: That’s inevitable. It’s pretty close to that, I think, already. I think the number of specialty drugs that will—I think the amount of spend in [specialty] pharmacy in 2019 is expected to be over 50% of the spend in pharmacy in general. So, just by looking at these numbers, it’s hard to say that specialty pharmacy is not here to stay.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Ramantamig's 93.6% ORR and Outpatient CRS Control
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5